Dr. Delfino Michael Crescenzo, MD

Dr. Crescenzo practices at Jamaica Hospital Medical Center in Jamaica, New York, part of MediSys Health Network.

Dr. Crescenzo's NPI, 1306828751, was assigned on November 18, 2005. Dr. Crescenzo holds New York license 137516.

Dr. Crescenzo's primary practice is Jamaica Hospital Medical Center, at 89th Avenue and Van Wyck Expressway, Jamaica, NY 11418 in Queens County. The practice phone is (718) 262-6000. Dr. Crescenzo also practices at Jamaica Hospital Medical Center, 89- Van Wyck Expy, Richmond Hill, NY 11418.

Dr. Crescenzo's primary practice is Jamaica Hospital Medical Center in Jamaica, New York, part of MediSys Health Network. The medical group on file is Premier Hematology & Oncology. Dmand AI also links Dr. Crescenzo to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crescenzo practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Crescenzo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Crescenzo is licensed in New York.

CMS data shows 216,311 Medicare services from Dr. Crescenzo across 23 procedure codes in 2024, for 377 Medicare patients. Medicare paid $350,333 for them.

CMS counts 377 Medicare patients who saw Dr. Crescenzo in 2024. The largest group is 75 to 84, with 146 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Crescenzo's median patient age at 42, with 76% women.

In 2024, Dr. Crescenzo wrote 1,555 Medicare Part D claims for 185 patients. 74% of them were for generic drugs. CMS names the drug for 1,157 of them, across 50 drugs with 11 or more claims each, at $1,661,189 in total drug cost. In 2023, CMS named 1,295 claims across 52 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Crescenzo for performance year 2024, reported individually. Dr. Crescenzo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Crescenzo as offering telehealth.

CMS Open Payments shows 251 general payments to Dr. Crescenzo from 43 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 86% of the total. Incyte Corporation paid the most, $783.